Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback